https://www.basg.gv.at/marktbeobachtung/amtliche-nachrichten/detail/chmp-meeting-highlights-februar-2026
CHMP Meeting Highlights Februar 2026 - BASG
Aktuelles aus dem Meeting vom 23.02.-26.02.2026 zu Neuzulassungen, Indikationserweiterungen, neu veröffentlichten EPAR's und kürzlich gestarteten Verfahren.
februar 2026chmpmeetinghighlights
https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-itvisma-spinal-muscular-atrophy-sma
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA) | Novartis
spinal muscular atrophynovartisreceivespositivechmp
https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-24-10-09-46-3280641
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat...
Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses Recommendation...
press releasefor eurecommendedapprovalchmp
https://www.basg.gv.at/gesundheitsberufe/das-chmp-stellt-sich-vor
Das CHMP stellt sich vor - BASG
daschmpsichvor
https://endpoints.news/sanofis-tolebrutinib-gets-chmp-backing-for-certain-ms-patients-after-fda-rejection/
Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection
Apr 24, 2026 - Sanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from the FDA in...
getschmpbackingcertainms